title: Current and planned multicenter trials for patients with primary or metastatic melanoma.
abstract: Multicenter clinical trials have established new standards of care in the surgical and medical management of malignant melanoma. They have led to the testing of new therapies and improved outcomes for patients with loco-regional and distant disease. Many pressing questions remain, however, and additional multicenter trials are currently underway to address them. The purpose of this review is to summarize relevant ongoing and planned multicenter trials that have and continue to define current melanoma management.
authors.affiliation: The Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA. vernon.sondak@moffitt.org
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
authors.forename: Dale
authors.initials: D
authors.lastname: Han
authors.forename: Jeremiah
authors.initials: J
authors.lastname: Deneve
authors.forename: Ragini
authors.initials: R
authors.lastname: Kudchadkar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D008197:Lymph Node Excision; D008545:Melanoma / Q000473:pathology / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D058990:Molecular Targeted Therapy; D015337:Multicenter Studies as Topic; D018714:Radiotherapy, Adjuvant; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents